Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Biogen advances Alzheimer’s tau program despite midphase miss
While the study failed to yield the hoped-for dose-response data, reductions in tau and cognitive benefits led Biogen to commit to a pivotal trial.
Nick Paul Taylor
May 14, 2026 8:35am
Regenxbio reaps pivotal win for Duchenne gene therapy
May 14, 2026 7:25am
Why Lexicon is in ‘good shape to go crazy’: CEO
May 13, 2026 10:50am
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
May 12, 2026 9:28am
Enterprise posts CF win, succeeding where Big Pharma stumbled
May 12, 2026 4:00am
Inhibrx’s OX40-Keytruda combo shows promise in early ph. 2 data
May 11, 2026 10:06am
